Poland buying Ecstasy

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Poland buying Ecstasy

These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format. All countries. Topics A-Z. The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses. Best practice. We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon. Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it. All publications. More events. More news. We are your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations. About the EUDA. MDMA is a synthetic drug chemically related to the amphetamines, but with somewhat different effects. In Europe, MDMA use has generally been associated with episodic patterns of consumption in the context of nightlife and entertainment settings. On this page, you can find the latest analysis of the drug situation for MDMA in Europe, including prevalence of use, seizures, price and purity and more. European Drug Report — home. The drug situation in Europe up to Drug supply, production and precursors. Synthetic stimulants. Heroin and other opioids. New psychoactive substances. Other drugs. Injecting drug use in Europe. Drug-related infectious diseases. Drug-induced deaths. Opioid agonist treatment. Harm reduction. Reported use of the drug appeared to decline temporarily during periods of social distancing during the early phases of the COVID pandemic. The currently available data would, however, suggest an overall relatively stable level of consumption but with national variations in the recent trends observed and the caveat that overall supply side indicators are suggestive of a slight recent decline in availability. About half of the European cities reporting wastewater analysis found an increase in MDMA residues between and , although in most other cities some decline was noted. Overall, available indicators suggest that MDMA production continues within Europe, both for domestic consumption and for export to non-EU markets. The information available is strongly suggestive that most MDMA production continues to be largely concentrated in or around the Netherlands. There are some signs of a reduction in the volume being manufactured in the most recent data. An important caveat here is that this information mostly covers the first years of the pandemic and needs to be interpreted with caution. In addition, while overall the average MDMA content of tablets and purity of powders remained stable in , a recent decrease in the MDMA content of ecstasy tablets was noted in some important source countries, most notably the Netherlands. With a typical MDMA content of to milligrams, the overall strength of tablets available on the retail marketplace still remains high by historical standards. It is difficult to interpret the more recent data with any certainty, but a possible decline in production volumes and some reductions noted in MDMA tablet content may indicate that producers have experienced greater problems sourcing precursor chemicals or that some producers may have switched to producing other substances, either because of market demand or because they are more profitable. It may also reflect a perceived consumer demand for lower-strength products. The use of MDMA is rarely cited as a reason for entering drug treatment in Europe but acute poisonings and deaths are sometimes associated with the consumption of this substance. The use of MDMA therefore continues to represent an important issue for prevention and harm reduction messaging and interventions. The availability of higher strength products potentially increases the risk of adverse health outcomes associated with the consumption of this substance. Interestingly, a decline in MDMA-related presentations by a quarter was observed in sentinel hospital emergency departments with data for and This data set, however, is difficult to interpret in respect to overall trends, as it is not nationally representative, has limited coverage and may reflect either changes in consumption or reporting during the pandemic. While it is again difficult to generalise due to limitations in national and European coverage, the available information from drug checking services suggests that MDMA products are generally less subject to adulteration than other illicit drugs they screened in This does occur however, as illustrated by the inclusion of synthetic cathinones in MDMA tablets observed on some occasions. These sorts of mixtures may also increase the risk to consumers of experiencing unexpected adverse effects and potential harm. This data explorer enables you to view our data on the prevalence of MDMA use by recall period and age range. You can access data by country by clicking on the map or selecting a country from the dropdown menu. Prevalence data presented here are based on general population surveys submitted to the EMCDDA by national focal points. For the latest data and detailed methodological information please see the Statistical Bulletin Prevalence of drug use. Graphics showing the most recent data for a country are based on studies carried out between and Mean daily amounts of MDMA in milligrams per population. Sampling was carried out over a week in March and April Show source tables. Back to list of tables. Homepage Quick links Quick links. GO Results hosted on duckduckgo. Main navigation Data Open related submenu Data. Latest data Prevalence of drug use Drug-induced deaths Infectious diseases Problem drug use Treatment demand Seizures of drugs Price, purity and potency. Drug use and prison Drug law offences Health and social responses Drug checking Hospital emergencies data Syringe residues data Wastewater analysis Data catalogue. Selected topics Alternatives to coercive sanctions Cannabis Cannabis policy Cocaine Darknet markets Drug checking Drug consumption facilities Drug markets Drug-related deaths Drug-related infectious diseases. Recently published Findings from a scoping literature…. Penalties at a glance. Frequently asked questions FAQ : drug…. FAQ: therapeutic use of psychedelic…. Viral hepatitis elimination barometer…. EU Drug Market: New psychoactive…. EU Drug Market: Drivers and facilitators. Statistical Bulletin home. Quick links Search news Subscribe newsletter for recent news Subscribe to news releases. This make take up to a minute. Once the PDF is ready it will appear in this tab. Sorry, the download of the PDF failed. Table of contents Search within the book. Search within the book Operator Any match. Exact term match only. No overall trend emerges from the data on MDMA use. Of the 11 European countries that undertook surveys since and provided confidence intervals, 1 reported higher estimates than their previous comparable survey, 9 reported stable estimates and 1 reported a decrease. Seizures of MDMA precursors increased to 2. The Netherlands, however, reported a lower average MDMA content of ecstasy tablets mg per tablet. MDMA market in Europe. Table 2. Prevalence of drug use in Europe, trends Country Country code Geographical scope Substance Recall period Age Austria AT National Table 3. Masaryk Water Resesrch institute, p. Table 4. Table 5. Table 6. Table 7. Table 8. Table 9. Table Main subject. Target audience. Publication type. European Drug Report main page. On this page. Forensic Toxicology Labs. Prevalence data presented here are based on general populaton surveys submitted to the EMCDDA by national focal points.

Poland: addicts are getting younger

Poland buying Ecstasy

The most common drug among Poles is cannabis, followed by sedatives and non-prescription hypnotics such as sleeping pills. In a survey conducted by the National Bureau of Drug Prevention in late , Of them, 9. According to results from the same survey. Poland, along with the Netherlands, is the country that consumes most ecstasy per capita in Europe. According to the latest EMCDDA report European Monitoring Centre for Drugs and Drug Addiction , Polish people are developing drug addictions at an increasingly earlier age: one year old in four has taken cannabis at least once in their life. This is the highest usage rate among that age group in Europe, followed by France, Spain and the Czech Republic. Data from the Polish Information Centre on Drugs and Drug Addiction is even more alarming: one year old in three has admitted having used marijuana or hashish. In recent years consumption has consistently been on the rise. According to a study by the Institute of Psychiatry and Neurology, the proportion of people experimenting with drugs increased by 14 percent from to Young Poles under 18 are the largest consumers of amphetamine and ecstasy in Poland. The survey results also show that use of illegal substances is almost as popular among young adults as adolescents. Drug legislation in Poland is some of the most restrictive in Europe. An anti-drugs law passed in July, allows people to be charged for the possession and distribution of any amount of banned substance. A person arrested in possession of even one gram of cannabis could receive a sentence of up to three years in prison. In recent years, statistics on the number of convictions related to the drug trade remain the same. However, the amount of people arrested and sentenced for being in possession of a small quantity of drugs for personal consumption increased by 1, over 10 years. Each year, 30, people are arrested for possession of illegal substances, 17, of whom were charged and 9, of whom were given prison sentences. In , the law designed to combat drug abuse saw a major amendment, which was passed in April and implemented in December The amendment was article 62a, giving prosecutors and judges the option to terminate criminal proceedings against individuals caught in possession of small amounts of narcotics and psychotropic substances for personal use. In addition, Article 70a obliges prosecutors to collect information on the use of narcotic drugs and psychotropic substances by the accused during the preparation phase of the criminal proceedings. This measure is intended to establish their level of dependence. Practice has shown that only in a few cases has the prosecutor decided to allow them the option afforded by Article 62a, to abandon criminal proceedings. The most recent national survey in Poland, conducted in , estimates a figure of , people who are dependent on drugs in a country of just over 38 million people equivalent to around 0. Following a law on the fight against drug addiction, drug treatment, rehabilitation services and help for re-insertion into society are available free of charge for drug-dependent people. They receive this help through specialised hospitals, outpatient clinics and public associations. The system of care for addicts consists mainly of forms of medium to long-term residential treatment. Residential clinics are mainly located outside urban areas and provide medical treatment and rehabilitation programmes based on the model of community therapy. According to the National Office of Drug Prevention, in there were 79 people in residential clinics and being treated in nearby outpatient clinics in Poland. There are also alternative treatments, but they are relatively rare: in , 2, patients were entitled to these, mainly in care units 25 people and in prisons seven. The majority were opiate users. Regarding prevention, policy action is defined by the new national programme to fight drug abuse, which was implemented in for a period of 5 years. One of its main features is to focus on both improving the quality of prevention programmes carried out in local communities, and also raising the skill set of the therapists who implement it. Finally, according to Ministry of Education regulations, schools are required to develop and implement a prevention policy. This rule also applies to the early identification of social maladjustment among young students, and the psychological and educational assistance to students and parents considered at risk from drugs. By Euronews. Share this article Comments. Share this article. You might also like Funeral home in Poland apologises after corpse falls out of hearse in traffic. Poland plans to further tighten rules on alcohol sales for under 18s. Polish town of Lewin Brzeski braces for dramatic flooding. Poland Europeans and drugs.

Poland buying Ecstasy